文献速递心外重症与机械循环支持冠心病外科

2018年美国心脏分配政策变更后持久性左心室辅助装置桥接患者移植后生存率降低:OPTN/UNOS登记分析

Reduced post-transplant survival in patients bridged with durable LVADs following the 2018 US heart allocation policy change: OPTN/UNOS registry analysis.
PubMed 文献 · J Heart Lung Transplant · 2026-04-30

该研究基于OPTN/UNOS登记数据,分析2018年美国心脏分配政策变更对持久性左心室辅助装置(LVAD)桥接患者移植后生存的影响。共纳入2014-2023年23,221例成人首次心脏移植受者,分为政策前/后及LVAD/非LVAD四组。结果显示政策后LVAD桥接患者等待时间缩短程度较小,且移植后1年和3年生存率均低于政策前,多变量Cox回归显示政策后LVAD与移植后死亡率增加独立相关(HR 1.26)。

要点

  • 2018政策后LVAD桥接患者移植后1年生存率从91.2%降至89.3%,3年从85.10%降至80.0%。
  • 政策后LVAD患者移植时病情更重:Karnofsky评分<50%者从36%增至53.7%,使用正性肌力药物者从8.1%增至20.6%。
  • 多变量分析显示政策后LVAD与移植后死亡率增加独立相关(HR 1.26,95%CI 1.12-1.43)。

核心结论

  • 2018年美国心脏分配政策变更改善了最危重患者移植可及性并降低等待列表死亡率,但LVAD桥接患者等待时间缩短程度较小,且当前时代移植后死亡率信号升高。

研究设计与样本

  • 回顾性队列研究,使用OPTN/UNOS登记数据,纳入2014年1月1日至2023年6月10日成人(≥18岁)首次心脏移植受者23,221例,按移植日期分为政策前(2014/1/1-2018/10/17)和政策后(2018/10/18-2023/6/10)两组,再按移植时LVAD状态分为四组,采用Kaplan-Meier法和多变量Cox回归分析。

主要发现

  • 政策后LVAD桥接患者比例从31.4%降至26.3%(p<0.001)。
  • 非LVAD受者等待时间从251天降至83天(减少67.1%,p<0.001),LVAD桥接受者从259天降至145天(减少44.0%,p<0.001)。
  • 政策后LVAD患者Karnofsky评分<50%者占53.7%(政策前36%,p<0.0001),使用正性肌力药物者占20.6%(政策前8.1%,p<0.0001)。
  • LVAD桥接患者移植后1年生存率政策前91.2%、政策后89.3%(p<0.0001),3年生存率从85.10%降至80.0%(p<0.0001)。
  • 非LVAD患者1年生存率政策前91.70%、政策后92.0%(p<0.001),3年生存率从86.2%降至83.5%(p<0.0001)。

关键数值与推荐

  • 多变量Cox回归显示政策变更后移植时LVAD与死亡率增加独立相关(HR 1.26,95%CI 1.12-1.43,p<0.001)。

临床怎么用

  • 临床应关注LVAD桥接患者移植后生存率下降的信号,优化候选者选择与围术期管理以改善结局。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: In 2018, the US implemented heart allocation changes to address evolving trends in waiting list mortality. This study examines the impact of the allocation changes on post-transplant survival in patients bridged with durable left ventricular assist devices (LVAD) compared to non-LVAD heart transplant recipients. METHODS: We used the OPTN/UNOS registry to identify adult (≥18 years), first-time, heart-only transplant recipients from 2014 to 2023. Recipients were categorized by date of transplant into PRE- (1/1/14-17/10/18) and POST- (18/10/18-6/10/23)groups and LVAD status at transplant (LVAD vs non-LVAD) to form 4 analytic groups. Survival outcomes were analyzed using the Kaplan-Meier method. Multivariable Cox regression was used to estimate adjusted associations with post-transplant mortality. RESULTS: A total of 23,221 HT recipients were included: 11,273 in the PRE (3,542 with LVAD and 7,731 without LVAD) and 11,948 in the POST (3,145 with LVAD and 8,803 without LVAD) era. Compared to PRE, the POST patients were younger (53.8, 52.8 vs 54.0, 54.2 years, p < 0.001) and had better renal function (1.2, 1.2 creatinine vs 1.3, 1.3, p < 0.001). The proportion of patients with LVAD at HT decreased from 31.4% in PRE to 26.3% in POST era (p < 0.001). POST mean waiting times were significantly reduced in non-LVAD recipients (251-83 days, 67.1% reduction, p < 0.001) and less so in bridged LVAD recipients (259-145 days, 44.0% reduction, p < 0.001). In the POST era, the acuity of LVAD candidates at transplant was higher-the proportion of LVAD patients with < 50% Karnofsky score was 36% PRE vs 53.7% POST (p < 0.0001) and the proportion of LVAD patients on inotropes was 8.1% PRE vs 20.6% POST (p < 0.0001). One-year post-transplant survival of patients bridged with LVAD was 91.2% PRE and 89.3% POST, p < 0.0001, and this difference increased further at 3 years - 85.10% PRE to 80.0% POST (p < 0.0001, Table 2). Meanwhile, 1-year survival in patients without LVAD was nominally similar PRE and POST-91.70% vs 92.0% (p < 0.001), and there was a smaller difference at 3-years-86.2% PRE vs 83.5% POST, p < 0.0001. Multivariable Cox regression showed that post-policy change, LVAD at transplant was independently associated with increased mortality (HR 1.26, 95% CI 1.12-1.43, p < 0.001). CONCLUSIONS: The 2018 heart allocation policy revision was effective in improving access to transplant for the most acutely ill patients and reducing waitlist mortality. However, the reduction of wait times was not realized to the same extent in LVAD-bridged patients, who also have a signal for higher post-transplant mortality in the current era. Our data provide insights into approaches that may mitigate this excess risk and ensure equitable outcomes for the increasingly complex population of patients bridged to transplant with durable LVADs.

来源:J Heart Lung Transplant,查看原文。版权归原作者所有。

引用

  1. Meyer JS, Zur A, Aravot D, et al. Reduced post-transplant survival in patients bridged with durable LVADs following the 2018 US heart allocation policy change: OPTN/UNOS registry analysis. J Heart Lung Transplant. 2026. PMID: 42069074. doi:10.1016/j.healun.2026.04.020

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。